REVEALING AND ACKNOWLEDGING VALUE JUDGMENTS IN HEALTH TECHNOLOGY ASSESSMENT by Hofmann, Bjørn et al.
International Journal of Technology Assessment in Health Care, 30:6 (2014), 579–586.
c© Cambridge University Press 2015
doi:10.1017/S0266462314000671
REVEALING AND ACKNOWLEDGING VALUE
JUDGMENTS IN HEALTH TECHNOLOGY
ASSESSMENT
Bjørn Hofmann
University College of Gjøvik and University of Oslo
Irina Cleemput
Hasselt University and Belgian Health Care Knowledge Centre (KCE)
Kenneth Bond
Canadian Agency for Drugs and Technologies in Health
Tanja Krones
University Hospital/University of Zu¨rich
Sigrid Droste
Institute for Quality and Efficiency in Healthcare (IQWiG)
Dario Sacchini
Institute of Bioethics, “Agostino Gemelli” School of Medicine, Universita Cattolica del Sacro Cuore
Wija Oortwijn
Ecorys Netherlands
Background: Although value issues are increasingly addressed in health technology assessment (HTA) reports, HTA is still seen as a scientific endeavor and sometimes contrasted
with value judgments, which are considered arbitrary and unscientific. This article aims at illustrating how numerous value judgments are at play in the HTA process, and why it is
important to acknowledge and address value judgments.
Methods: A panel of experts involved in HTA, including ethicists, scrutinized the HTA process with regard to implicit value judgments. It was analyzed whether these value judgments
undermine the accountability of HTA results. The final results were obtained after several rounds of deliberation.
Results: Value judgments are identified before the assessment when identifying and selecting health technologies to assess, and as part of assessment. They are at play in the
processes of deciding on how to select, frame, present, summarize or synthesize information in systematic reviews. Also, in economic analysis, value judgments are ubiquitous.
Addressing the ethical, legal, and social issues of a given health technology involves moral, legal, and social value judgments by definition. So do the appraisal and the
decision-making process.
Conclusions: HTA by and large is a process of value judgments. However, the preponderance of value judgments does not render HTA biased or flawed. On the contrary they are
basic elements of the HTA process. Acknowledging and explicitly addressing value judgments may improve the accountability of HTA.
Keywords: Morals, Ethics, Technology Assessment, Biomedical, Personal value, Morality, Biomedical technology assessment, Values, Norms
Are value judgments important in health technology assessment
(HTA)? A recent study indicates that this is the case: 90 percent
of 104 responding HTA experts, publishing in this journal be-
tween 2005 and 2007, agreed that healthcare decisions involve
value judgments and that ethical analysis is important to HTA
(1). However, the response rate was 16 percent, and respon-
dents’ views on the role and place of value judgments were not
clear. Traditionally, HTA and evidence-based medicine (EBM)
have been considered to be a scientific and value-free endeavor
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(2). Ethicists working in the field of HTA experience that a
significant number of HTA experts think that value judgments
threaten the presumably “objective scientific” basis of HTA,
making it subjective, relative, and unreliable, as a distorting
“bias.” Value judgments, and in particular social value judg-
ments, are frequently considered to be external to HTA, and
are best addressed by experts (in ethics) and decision makers
after the “real” HTA is finished. This “externalist” conception
of value judgments in HTA is illustrated in Figure 1.
Although the clear distinction between facts and values is
difficult to defend philosophically (3), it appears to be strongly
present in the current concept and use of HTA, for example,
in the distinction between assessment and appraisal, between
systematic review and personal preferences, between scientific
judgments (e.g., the EBM analysis) and the social judgments.
While parliamentary technology assessment (PTA) explicitly
addresses value issues, HTA has been more reluctant to do so
(4). One may argue that there is within the HTA community
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Figure 1. Adapted from Tunis SR. Reflections on science, judgment, and value in evidence-based decision making: A conversation with David Eddy. Health Aff. 2007;26(4) w500-w515, with permission
a “Cartesian Angst” a “fear of ending in relativism and ni-
hilism when one departs from the analytical-rational scientific
tradition that has dominated Western science since Descartes”
(5) that perpetuates this reluctance. From the externalist per-
spective, value judgments represent a “bias” to be avoided or
eliminated.
In this study, we reject the hypothesis that HTA can be free
of value judgments. We will do so by illustrating how value
judgments are necessarily involved in various crucial steps of
the HTA process: identification, priority setting, assessment,
appraisal, and implementation in policy and practice. Further-
more, we will argue that value judgments are of constitutive
importance to HTA. Evaluation of technology involves value
judgments as does the involvement of different stakeholders in
the HTA process, such as scientists, decision makers, patient
representatives, health professionals, and industry representa-
tives. Moreover, making explicit the value judgments implicit
in HTA (e.g., in the framing of the research question) as well as
in the appraisal phase (weighing the information provided) can
make HTA more open, transparent, and trustworthy, as well as
promoting accountable and robust decision making.
METHODS
A panel of international HTA experts (twelve from nine coun-
tries) specialized in applying methodology in ethics for HTA
met during a 2-day workshop on methodology in ethics for
HTA in Cologne on January 19–20, 2012. The workshop was
hosted by The Institute for Quality and Efficiency in Health-
care (IQWiG) and organized by the INAHTA/HTAi Ethics In-
terest Sub-Group on Ethical Issues in HTA (EISG). All par-
ticipants contributed to the workshop, presenting their experi-
ences with how value issues were acknowledged and addressed
in HTA. The role of value judgments and approaches to ex-
plicitly address value judgments were discussed. In particu-
lar, the panel of experts scrutinized the various parts of the
HTA process for implicit value judgments. Identified value
judgments were then analyzed critically with respect to their
role for the accountability of HTA results. The final results
were elaborated after four rounds of deliberation through e-mail
correspondence.
RESULTS
Value Judgments in Conducting HTA
Value judgments are judgments about what is good. However,
things can be good in many ways. They can be good in and
by themselves (intrinsic values) or because they result in some-
thing good (extrinsic values). The objective of health technology
(HT), obtaining health, is considered by many to be an intrinsic
value, while HT can be of extrinsic value in so far as it results
in something good. There are many types of goodness, such as
scientific, economic, technical, medical, professional, aesthetic,
and moral goodness (6).
As HTA is an evaluation of the goodness of an HT, it must
consist of value judgments. In HTA we strive to use scientif-
ically good (i.e., robust) methods, implement medically good
outcomes (e.g., better health), in morally good ways, to fa-
cilitate socially acceptable decisions, at bearable costs. In this
we make moral, methodological, legal, economic, and social
value judgments, and sometimes they are intertwined to such
an extent that it is difficult to tell them apart. Values are also
at the core of EBM (7). Setting limits to p-values and confi-
dence intervals are based on (epistemological) value judgments.
This means that values and value judgments are constitutive
to HTA, both in assessment and in appraisal (8;9). Moreover,
value judgments are at play already before assessment, that is,
in the decision to conduct a HTA, in the selection of technolo-
gies to be assessed, as well as in the formulation of research
questions.
The following values have been identified in the HTA pro-
cess (9).
Moral values. For example, to help persons who require as-
sistance in situations that are undesirable to them and that can
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Table 1. Values Related to Technology, Using Diagnostic Ultrasound as an Example
Teleological level Overall level Particular level: e.g. ultrasound
Function To uncover information To produce an image of intracorporeal anatomical structure by means ultrasound reflections
Purpose To gain knowledge To recognize conditions, to diagnose
Intention To obtain choice of action To make prognosis, treat, prepare for emergencies, (sex) selection
Higher order intention To promote progress Ultrasound device as a symbol of progress. (argumentum ad novitatem)
Note. From Hofmann B. When means become ends: Technology producing values. seminar.net 2006; 2(2): 1–12.
be related to conditions considered to be bodily or mentally
harmful.
Value of assessing technology. It is believed that HTA is a
good way to assess healthcare technology, and we need no proof
thereof. That is, HTA has a positive value.
Selection of technology to assess. As already indicated, the
prioritization of which technology to assess is as evaluative as
is the prioritization to which the assessment leads.
Values of knowledge. There are epistemological values in HTA,
for example, goodness of: (i) inquiry: reproducibility, exacti-
tude, completeness, consistency and coherence, as well as; (ii)
study design hierarchy (e.g., randomized clinical trials (RCTs)
over observational studies); (iii) study quality (e.g., according to
Grading of Recommendations Assessment, Development and
Evaluation, GRADE); (iv) endpoints and outcome measures
(definition, selection, and construction of endpoints); (v)
Comparator. (selection).
Social values. Values related to the implications of implement-
ing the HT for the patients’ good life and for the communal
welfare.
Technological values:Technology is related to values on several
levels. See Table 1.
Value Judgments in Selection and Presentation of HTA Results
As the selection of studies to include in a systematic review
is based on value judgments, so is the presentation of results
and the summary or synthesis of information. How the results
are framed, is based on value judgments: which end-points we
choose; how do we measure the end-points; which results (stud-
ies) we include; how we balance burdens and benefits, and what
we include (and exclude) in the summary.
Interpreting qualitative measures, as given in legislation or
guidelines also involves value judgments, for example, require-
ments of “additional benefit” in order for a HT to be imple-
mented, may be represented by thresholds or intervals by HTA
agencies.Moreover, such thresholdsmay vary between outcome
measures, for example, between “hard” and “soft” end-points.
Such interpretations and weightings are based on value judg-
ments, which are not always made explicit.
Value Judgments in Economic Analysis of HTA
The measurement of societal preferences for the distribution of
health gains has always played an important role in health eco-
nomics. However, the implicitly assumed desire (preferences) to
maximize health in economic evaluations may not correspond
to how the majority in a society think health ought to be dis-
tributed (values), a fact that bears directly on the objective of
resource allocation (10). The question is whether it is really
health the society wants to maximize or whether it is some-
thing else, for example, capabilities. If so, health economic
evaluations, that most often still use health as a denominator in
the cost-effectiveness ratio, are not the right decision-making
tool.
Cost-effectiveness analyses (CEA) presupposes that “a
QALY is a QALY,” equally weighted across individuals which
is a quasi-egalitarian value judgment. This value judgment is
questionable in many circumstances and correcting for this de-
ficiency is not straightforward.
Cookson et al. (11) presented four approaches to incor-
porating equity considerations into economic evaluations: (i)
provide factual information about equity, (ii) perform an eq-
uity impact assessment, for example, using health inequality
indices, (iii) analyze the opportunity cost of equity, and (iv)
assign equity weights to health outcomes in the economic eval-
uations. The level of quantification of the equity concerns dif-
fers, with the first approach having the lowest and the fourth
approach having the highest level of quantification. It should
be noted that any weighting system for QALYs in CEAs will
be incomplete or complicate the analysis, as there are so
many potential dimensions of equity. A fifth approach, is to
use fully quantified multi-criteria decision analysis (MCDA)
(12).
The technical development of CEA also involves important
value judgments through the methodological choices that are
made at different stages during the analysis. For illustration, we
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highlight three such decision points: the choice of perspective,
the target population, and the outcome measure.
The societal perspective is often explicitly argued for, al-
though other perspectives are frequently used, often for legiti-
mate reasons such as concerns about the ethical implications of
methodological limitations for measuring costs and outcomes
from a societal point of view (13). However, by taking a health-
care payers’ perspective, it is judged that societal costs outside
the healthcare sector, for example, productivity losses, should
not determine a healthcare reimbursement decision. However,
when productivity losses are included in the analysis, the choice
of the unit cost of a day off of work suggests a value judg-
ment. For example, if the wage of the person on sick leave
is taken as the relevant unit cost, the productivity loss of a
person performing higher paid work is valued more highly
than the productivity loss of a person performing lower paid
work.
For the definition of the target population, there is a dis-
tinction between clinical medicine and public health interven-
tions. In clinical medicine, the societal importance of equality
makes it unacceptable to discriminate between target groups
by income, age, sex, or ethnicity in the provision of health
care (11). Public health interventions, in contrast, may be ori-
ented toward reducing health inequalities, so targeting of in-
terventions is considered acceptable up to a certain point (11).
Nevertheless, economic evaluations often distinguish between
sub-groups for both types of interventions to demonstrate dif-
ferential cost-effectiveness across population sub-groups. CEA
thus show what the choice for equal access suggests in terms of
reduced cost-effectiveness, but typically fail to identify, mea-
sure, and value health inequality impacts. As a result, decisions
based on such information (or lack of it) rely on implicit value
judgments about how equity ought to be conceptualized and
balanced with efficiency.
Another value based choice in the economic evaluation
process concerns the outcome measure used in the cost-
effectiveness ratio. The two most frequently used generic out-
come measures are life years gained (LYG) and QALYs gained.
Although the impact of health interventions on health-related
quality of life (HRQoL) is generally considered important, some
may prefer LYG as an outcome measure for CEA because of
its objective nature and the lack of consensus on methods for
measuring HRQoL. Because the valuation of health states dif-
fers between those who experience a health state directly and
those who do not, the outcome of the cost-effectiveness anal-
ysis will differ depending on whose values are used. Two ap-
proaches to this problem exist: either an explicit choice is made
regarding whose values should count or the impact on HRQoL
needs to be considered separately, if it is considered valuable
at all. The QALY approach also embodies value judgments
regarding the trade-off between HRQoL (and its various di-
mensions) and length of life (14). For example, 2 years of extra
life expectancy at a HRQoL of 0.5 (1 QALY) are valued equal
to 10 years of extra life expectancy at a HRQoL of 0.1 (also
1 QALY).
Ethical, Legal, and Social Values
“Ethical, legal, and social issues” (ELSIs) are together with
organizational issues crucial to the assessment of HTs. ELSIs
address the conditions and consequences of the implementation
and use of HTs, related to the individual, to specific groups,
and to society at large. This means ELSIs are closely related to
societal settings and societal dynamics, and as such involve a
wide range of moral, legal, and other social value judgments.
For the assessment of many HTs these value judgments are in-
tertwined, but as will be described below, for certain parts of the
HTA process or for particular HTs, it is fruitful to differentiate
between moral, legal, and social value judgments.
Many new technologies, such as preimplantation genetic
diagnosis, have posed basic moral challenges and sparked de-
bate. Other technologies have challenged religious, social, or
cultural conceptions, for example, cochlear implants have in-
cited debates on whether deafness is a functional defect or a
characteristic of people sharing a special (sign) language. Some
technologies have challenged (and changed) the legal frame-
work in some countries, such as genetic testing. Organizational
issues have come to focus as a result of other technologies.
However, value judgments are not only present in contro-
versial technologies, but also present, though more subtly, with
traditional HTs. Hence, analyses of ELSIs may highlight in-
herent and hidden value judgments in noncontroversial HTs.
How much, and which, ELSIs and organizational issues that
are addressed, may vary between different countries. It may be
important to be aware of such contextual differences to promote
sound reasoning and robust decision making.
Even though the importance of ELSIs may be generally
accepted, only few institutions are systematically integrating
ELSIs and organizational issues in their assessments (15–17).
Moreover, ILSIs are addressed selectively, with implicit selec-
tion criteria. Such approaches risks failing to identify and ad-
dress the implicit and covert values involved in implementing
HTs. To avoid such shortcomings and to promote openness
and transparency in the HTA process, ELSIs and organizational
issues should be addressed in a systematic way.
Legal issues are of significance because (a) HTs are subject
to rules and regulations (e.g., patents/licenses/approvals), (b)
HT assessment is subject to legislation, and (c) patients’ basic
rights to health care are given by law (18). Values and norms are
inherent in legislation and are the drivers for changing existing
laws and regulations. Legal value judgments may be contextual
as laws may be regional or national.
Value Judgments in Appraisal and Decision Making
The appraisal process considers the outputs of the assess-
ment within the context of additional information supplied by
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relevant parties for the decision-making process. Nowadays,
some European countries have explicit processes in place mak-
ing use of multi-stakeholder consultations (e.g., for coverage
decision making in the Netherlands) or direct stakeholder in-
volvement in appraisal committees (e.g., for pharmaceutical
reimbursement in Belgium). Various methods for identifying
and handling values in the appraisal stage exist, such as the
UK National Health Service (NHS) guidance on social val-
ues and the Ontario Health Technology Advisory Committee
(OHTAC)’s use of Daniels and Sabin’s “accountability for rea-
sonableness” framework. However, other less formalized or
explicit decision-making processes are also used in making
reimbursement decisions on HTs (19). Hence, how to de-
fine appraisal and the assessment-appraisal border, as well as
how to organize the appraisal process, involves a series of
value judgments, such as who should do the appraisal, who
should be involved and how should stakeholders be involved
(20).
In the appraisal process a judgment is made on the rel-
ative importance of a range of factors that differ from ap-
praisal to appraisal. These factors could be, for example, bur-
den of disease, extent of individual responsibility, effectiveness,
cost-effectiveness, and budget impact. However, such factors
are valued differently by patient representatives, health profes-
sionals, policy makers, payers, academic researchers, industry
members, carers, citizens, etc. involved in appraisal commit-
tees. When stakeholders make value judgments with regard to
the aforementioned factors, it may result in different effects on
resource allocation. This has been demonstrated in a study of
selected HTAs in The Netherlands, including the application
of a growth factor (GM-CSF) as an adjunct to chemotherapy in
treating elderly peoplewith acute leukemia, evaluation of cervix
smears by using a semi-automatic system (PAPNET), infertil-
ity diagnostics, lung transplantation, extra-corporal membrane
oxygenation in neonates, and cochlear implants by prelingual
deaf children (21).
Value judgments are constitutive in decision making: “. . .
some person or some organization needs to make a judgment
about whether the quality of a particular body of evidence is
adequate to make a particular decision” (22). However, the prin-
ciples and values governing the aspects of resource allocation,
rationing, and prioritization vary with the context. Fair alloca-
tion decisions are expected to concern all relevant stakeholders.
However, the principles and considerations that people think
are important or relevant differ. An analysis of selected debates
about inclusion of HTs in the benefit package in The Nether-
lands showed that stakeholders interpret “necessary care” in at
least three different ways (individualmedical need, effective and
cost-effective health care, and [normal] social participation);
this has led to confusion and questions about fair resource allo-
cation (23). Open and explicit procedures for decision making
are requirements for legitimate decision-making processes. In
addition, whether actors in decision making are equal partners
and whether their arguments are assessed on a basis of con-
vincing evidence and sound arguments, is related to values, for
example, institutional and social values. In addition, processes
are valued for being transparent, efficient, and sustainable. “Nei-
ther science nor economics will resolve the pain of choice. The
best we can hope for is to strive to improve the process by which
we reach the decisions” (24).
DISCUSSION
A Value Judgment Is not a “Bias”
Our scrutiny of the various parts of an HTA process shows how
value judgments permeate all levels of what is considered to
be the scientific endeavor of HTA (assessment, appraisal, and
HTA-based decision making). Our analysis also reveals that
the value judgments are not alien to the HTA process. On the
contrary they are constitutive to HTA, for example, selecting
end-points and deciding on comparators are natural parts of the
HTA process.
Many of the value judgments are implicit or tacit, and, by not
making them explicit, the illusion of scientific objectivity and
neutrality is reinforced. However, by leaving these judgments
implicit, they may cloak important value issues and controver-
sies and, as such, frame or “bias” the decision-making process.
Hence, ignoring value judgments in HTA may make it more
“biased” than addressing them. Accordingly, we contend that
making value judgments explicit can improve the quality of the
HTA and the decision-making process.
For example, in the case of treatments for adult obesity, the
ethics analysis revealed implicit assumptions and value judg-
ments involved in framing and conducting the assessment. A
consequence was that certainties in the policy analysis became
uncertain. This can be frustrating as we yearn for clear facts for
clear-cut decisions. However, the reasoning of the policy analy-
sis may be made more accountable and valid because it then
more accurately reflects the actual situation. The reasoning may
be sounder because implicit assumptions were made apparent
and could then be the focus of discussion. Stakeholders can
then have an equal opportunity to understand what is at stake
and to participate in the discussions and reflect on the impact of
a technology. As a result of making value judgments explicit,
assumptions are more likely to be justified and the assumptions
and the claims they buttress are more likely to be connected
appropriately.
Therefore, making the value judgments of the HTA process
and the “scientific judgments” of HTA explicit, clear, and trans-
parent can provide the basis for more sound and sustainable
decisions and, as such, enrich HTA.
How to Address Value Judgments?
As we have tried to show, value judgments are at the core of
HTA, they are part of its raison d’eˆtre and its entire process.
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To highlight the values of the facts and processes of HTA is
important. However, to question the strict border of science and
ethics, assessment and appraisal, does not mean that separating
assessment, appraisal and decisionmaking does notmake sense.
They represent different kinds of value judgment in different
contexts.
On the basic assessment level, it seems useful to make
the process of defining, constructing, and evaluating effects
and end-points explicit and discuss the reasons why specific
comparators and thresholds were chosen and how. To make
well-considered value judgments explicit on different levels,
calls for specific approaches. Methods developed for doing
ethics in HTA (11;16) may be useful for highlighting moral
(and legal) value judgments in the process of conducting HTA.
Moreover, several methods are available for addressing val-
ues and arguments, see Table 2. The value base of HT may
be as important as its evidence base and core values may
be elaborated for HTA, such as universal access, freedom of
choice, and quality care (25). Macro-level reflections on the
general values of health care (health, wellbeing, welfare) and
its philosophical underpinnings, such as equity, equality (and
its specific forms), maximization of health or preferences or
social values are needed and should be more widely known
and explicitly used. This can be promoted by guidelines on
how and why to conduct HTA and in appraisals and decision
making.
In economic evaluations, no quick fixes exist. There seems
to be no consensus on how to deal with the key elements of
equity. Therefore, scenarios could be presented in the assess-
ment to show the results of a cost-effectiveness analysis based
on choices reflecting different value judgments. The key is-
sue will be explicitness about the value assumptions and judg-
ments made during an assessment process, in other words,
to declare the ethical framework underlying the economic
analysis.
A clear and transparent exposition of value judgments made
during the HTA could be matched with the relevant societal
values. As such, the appraisal process can remain deliberative,
while the assessment can remain descriptive. It might be useful
to first acquire a full understanding of the decision-making
context and societal values and to figure out its consequences for
the perspective, outcomemeasures, the discount rates and equity
issues to be considered (13). Such an approach would reduce
the number of scenarios to consider in a particular context.
Less sanguinely, we acknowledge that to include all of these
reflections into an HTA may render it rather extensive and less
user-friendly, as well as less transferable to other countries and
contexts. However, not all value judgments may be as press-
ing and challenging in every assessment. Moreover, for HTs
involving a wide range of value judgments, the awareness of
this complexity may be painful to decision makers. However,
the complexity of value judgments may better reflect what is at
stake. A “quick fix” is most often neither quick nor a real fix.
Moreover, another group of experts could identify and em-
phasize other value judgments, and our panel would be able
to continue the work and identify additional value judgments.
They (or we) may also suggest other methods for addressing
the value judgments. However, all value judgments identified in
this article are found in the HTA literature. Hence, they should
not be unfamiliar to a well-informed HTA expert. Nevertheless,
we acknowledge that more research on how to highlight and
integrate value judgments in HTA is needed.
CONCLUSIONS: VALUE JUDGMENT IN HTA: FROM FOE TO FRIEND
We started with a notion of Cartesian Angst (anxiety) for value
judgments which we have experienced with several of our HTA
colleagues and which may help to explain the difficulty with
addressing value judgments in HTA and with integrating ELSIs
in HTA. Our analysis identifies value judgments at all levels of
HTA, and reveals how they are constitutive to HTA. We suggest
a relief of the Cartesian Angst: by accepting value judgments,
making them explicit, and considering them openly, the HTA
processmay becomemore accountable.We suggest amove from
an “externalist” conception of value judgments that views value
judgments as something “added” to the results of an HTA to an
“internalist” one that acknowledges and openly addresses value
judgments as they arise within the entire HTA process. We also
refer to several ways to address the inherent value judgments
in practice. Accordingly, acknowledging and addressing value
judgments may improve HTA.
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Table 2. Guidance Literature on How to Identify and Address Values in HTA
Kind of values Guidance literature
Moral values Assasi N, Schwartz L, Tarride JE, Campbell K, Goeree R. Methodological guidance documents for evaluation of ethical considerations in health technology
assessment: A systematic review. Expert Rev Pharmacoecon Outcomes Res 2014; 14(2): 203–220.
Bombard Y, Abelson J, Simeonov D, Gauvin FP. Eliciting ethical and social values in health technology assessment: A participatory approach. Soc Sci Med 2011;
73(1): 135–144.
Boyd CM, Singh S, Varadhan R, Weiss CO, Sharma R, Bass EB, et al. Methods for benefit and harm assessment in systematic reviews. Rockville (MD): Agency for
Healthcare Research and Quality; 2012.
Burls A, Caron L, Langavant GCd, Dondorp W, Harstall C, Pathak-Sen E, et al. Tackling ethical issues in health technology assessment: a proposed framework. Int
J Technol Assess Health Care 2011; 27(3): 230–237.
European Network for Health Technology Assessment EUnetHTA, The HTA Core Model∗: Version 2.0. Helsinki: National Institute for Health and Welfare (THL);
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